InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: mldillon post# 154788

Thursday, 03/25/2021 3:06:44 PM

Thursday, March 25, 2021 3:06:44 PM

Post# of 233271

"Given these data suggest a potentially important clinical benefit in a pre-defined sub-group of high-risk patients and the public health need, GSK has decided to amend the OSCAR study to expand this cohort to confirm these potentially significant findings"

Is this not what CytoDyn has done/is doing with leronlimab?



100%! GSK's trial does not deserve an EUA right now. GSK's trial did have better data than CYDY's. But GSK needs to do another study with higher dosage and see the results. HGEN's lenzilumab did all their trials with a dosage 20 times as large as GSK.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News